Survival Analysis and Prognostic Factors for Neuroendocrine Tumors in Turkey

Abstract

1-90 months). The three-year overall survival rate was 71%: 100% in stage I, 88% in stage II, 80% in stage III, and 40% in stage IV. The three-year survival rate was 78% in tumors localized in the gastroenteropancreatic region, and 54% in tumors localized in other organs. In the univariate analysis, gender, age, performance status of the patients, grade, localization, surgical treatment, and neutrophil/ lymphocyte ratio (≤5 versus >5) affected the prognosis of the patients. Conclusions: Most of the tumors were localized in the gastroenteropancreatic region, and the three-year survival rate in tumors localized in this region was better than the tumors localized in other sites. Surgical treatment was a positive independent prognostic factor, whereas Grade 3 and a neutrophil/lymphocyte ratio of >5 were negative independent prognostic factors.

Neuroendocrine tumors in the Iran Cancer Institute: Predictive Factors of Patient Survival

“…The primary origin of the tumor was unknown in 32 patients. Our results are in accordance with a similar conducted research in Turkey in which gastrointestinal and lung have been reported as major sites of neuroendocrine tumors (Yocel, et al 2013). In a study by Sorbye and colleagues the primary tumor site was pancreas and colon in 64 patients (Sorbye et al, 2013).…”

Best prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single-center study

“…Consistent with other studies, our study demonstrates improved survival rates with curative surgery (23)(24)(25). A multidisiplinary approach, including surgery, somatostatin analogues, chemotherapy, targeted therapy, and peptide receptor radionuclide therapy (PRRT), should be considered, and treatment should be individualized for patients with NETs.…”

Analysis on the Characteristics and Prognosis of Pulmonary Neuroendocrine Tumors

“…Pulmonary NET could be clinically, radiologically, and pathologically classified into four subtypes: TC, AC, LCNEC and SCLC (Haghighi et al, 2012;Liu et al, 2013;Yucel et al, 2013;Zahir et al, 2013;Zeng et al, 2013). They represent a specific group of tumors with heterogeneous histological patterns and clinical behaviors.…”